Imipridones for gliomas
View Patent ↗Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided.
1. A method of treating cancer in a subject in need thereof, comprising: administering to the subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount compound (1)
or a pharmaceutically acceptable salt thereof, wherein the cancer is a glioma having a histone H3 K27M mutation.
2. The method according to claim 1 , wherein the glioma is selected from the group consisting of a diffuse intrinsic pontine glioma, a diffuse midline glioma, a spinal cord glioma, a thalamic glioma, a brainstem glioma, and a cerebellar glioma.
3. The method according to claim 1 , wherein the glioma is not a spinal cord tumor.
4. The method according to claim 1 , wherein the histone H3 K27M mutation in the glioma is H3.3 K27M or H3.1 K27M.
5. The method according to claim 1 , wherein the histone H3 K27M mutation in the glioma is in one or more histone genes selected from H3F3A, H3F3B, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, or HIST1H3J.
6. The method according to claim 1 , wherein in cancerous tissue DRD2 is overexpressed, DRD5 is underexpressed, or both.
7. The method according to claim 1 , wherein the subject is a human.
8. The method according to claim 1 , wherein the subject is a domesticated pet.
9. The method according to claim 1 , wherein the subject is a pediatric subject.
10. A method of treating cancer in a subject in need thereof, comprising: administering to the subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount a compound of formula (10) or an analog thereof, or a pharmaceutically acceptable salt thereof, wherein the cancer has a histone H3 mutation.
11. The method according to claim 10 , wherein the cancer is selected from the group consisting of a central nervous system tumor, a brain tumor, a peripheral nervous system tumor, a pheochromocytoma, a paraganglioma, an adrenal cortical carcinoma, an adrenal tumor, and a neuroendocrine tumor.
12. The method according to claim 10 , wherein the cancer is selected from the group consisting of meningioma, ependymoma, glioma, neuroblastoma, and diffuse intrinsic pontine glioma.
13. The method according to claim 10 , wherein the cancer is selected from the group consisting of a diffuse midline glioma, a spinal cord glioma, a thalamic glioma, a brainstem glioma, and a cerebellar glioma.
14. The method according to claim 10 , wherein the histone H3 mutation is H3.3 K27M or H3.1 K27M.
15. The method according to claim 10 , wherein the cancer has a K27M mutation in one or more histone genes selected from H3F3A, H3F3B, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, or HIST1H3J.
16. The method according to claim 10 , wherein DRD2 is overexpressed in cancerous tissue.
17. The method according to claim 10 , wherein the subject is a human.
18. The method according to claim 10 , wherein the subject is a domesticated pet.
19. The method according to claim 10 , wherein the compound is ONC201.
20. The method according to claim 10 , wherein the subject is a pediatric subject.
21. A method of treating cancer in a subject in need thereof, comprising: administering to the subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount a compound of formula (10) or an analog thereof, or a pharmaceutically acceptable salt thereof, wherein the cancer is a midline glioma.
22. The method according to claim 21 , wherein the cancer is selected from the group consisting of a diffuse intrinsic pontine glioma, a diffuse midline glioma, a spinal cord glioma, a thalamic glioma, a brainstem glioma, and a cerebellar glioma.
23. The method according to claim 21 , wherein the cancer is not a spinal cord tumor.
24. The method according to claim 21 , wherein the cancer has a histone H3 mutation, wherein the histone H3 mutation is H3.3 K27M or H3.1 K27M.
25. The method according to claim 21 , wherein the cancer has a histone H3 K27M mutation in one or more histone genes selected from H3F3A, H3F3B, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, or HIST1H3J.
26. The method according to claim 21 , wherein DRD2 is overexpressed in cancerous tissue.
27. The method according to claim 21 , wherein the subject is a human.
28. The method according to claim 21 , wherein the subject is a domesticated pet.
29. The method according to claim 21 , wherein the compound is ONC201.
30. The method according to claim 21 , wherein the subject is a pediatric subject.